Model confirms active surveillance as viable option for men with low-risk prostate cancer

September 24, 2012

A new research model has estimated that the difference in prostate cancer mortality among men with low-risk disease who choose active surveillance versus those who choose immediate treatment with radical prostatectomy is likely to be very modest, possibly as little as two to three months.

The model, developed by biostatistician Ruth Etzioni, Ph.D., and colleagues of the Public Health Sciences Division at Fred Hutchinson Cancer Research Center in Seattle, Wash., is among the first to use specific data from published studies to project the likelihood of mortality among men with low-risk disease who choose active surveillance. The study was published in , a journal of the American Association for Cancer Research.

"We are now diagnosing many more men with low-risk prostate cancer, a large fraction of whom would never have known they had disease in the absence of screening," Etzioni said. "These men have cancers that may not have caused them harm if they had not been detected through screening, and we are faced with the dilemma that not all of these men will benefit from treatment."

The alternative to treatment, known as watchful waiting or active surveillance, was backed by the National Institutes of Health as a viable option during a State-of-the-Science Consensus in December 2011. However, the approach is supported by little data due to the length of time required to measure its effect on prostate cancer mortality.

In this study, Etzioni and colleagues developed a to estimate prostate in men who would undergo active surveillance and compared that with the mortality of men treated with immediate radical prostatectomy. Using data from separate patient groups, they populated their model with time from diagnosis to treatment for men undergoing active surveillance, time from surgery to recurrence for men undergoing radical prostatectomy and time from recurrence after prostatectomy to death.

The model projected that 2.8 percent of men who undergo active surveillance would die from their disease within 20 years of their diagnosis compared with 1.6 percent of men who undergo immediate . The reduced risk for by undergoing immediate amounted to an average of 1.8 months of additional life per patient. In comparison, those men who chose active surveillance would have an average of 6.4 years of life free from treatment and its side effects.

"Although this is not a new result, it is confirmation of what we expected and it substantiates data from previous studies looking at watchful waiting," Etzioni said. "Very few men with low-risk disease die from prostate cancer regardless, and the difference between treatments appears to be very modest."

It will be important to begin to measure quality of life between these two groups. Although immediate treatment is associated with both short-term and long-term side effects, including impotence and incontinence, active surveillance might also have an effect on a patient's quality of life.

"That six-year treatment-free interval means that men who choose will not have to endure treatment side effects during that time, but whether that is replaced by a negative impact on quality of life because of anxiety or repeat biopsies is not well known," Etzioni said.

Explore further: Screening debate typifies prostate cancer uncertainties

Related Stories

Screening debate typifies prostate cancer uncertainties

August 10, 2012
(HealthDay) -- Though prostate cancer makes the news a lot, much of the information seems conflicting or inconclusive, leaving men with few absolute answers.

Active surveillance up in multidisciplinary prostate CA care

August 1, 2012
(HealthDay) -- Men with low-risk prostate cancer are more likely to pursue active surveillance when seen at a multidisciplinary prostate cancer clinic rather than when they see individual specialists in sequential settings, ...

Active surveillance cost-effective for prostate cancer

July 13, 2012
(HealthDay) -- In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, according ...

Radical prostatectomy doesn't cut mortality versus observation

July 19, 2012
(HealthDay) -- For men with clinically localized prostate cancer, radical prostatectomy does not significantly reduce all-cause or prostate-cancer mortality compared with observation through 12 years of follow-up, according ...

Recommended for you

Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

December 11, 2017
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects ...

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.